BMJ:药物成瘾患者阿片类药物替代治疗期间和治疗后的死亡风险几何?

2017-05-27 吴刚 环球医学

阿片类药物依赖是日益严峻的药物使用问题,造成全球疾病负担。2017年4月,发表在《BMJ》的一项由西班牙、澳大利亚和葡萄牙科学家进行的队列研究的系统评价和Meta分析,考察了阿片类药物替代治疗期间和治疗后的死亡风险。



阿片类药物依赖是日益严峻的药物使用问题,造成全球疾病负担。2017年4月,发表在《BMJ》的一项由西班牙、澳大利亚和葡萄牙科学家进行的队列研究的系统评价和Meta分析,考察了阿片类药物替代治疗期间和治疗后的死亡风险。

目的:旨在比较阿片类药物依赖的患者中,美沙酮或丁丙诺啡替代治疗期间和治疗后,全因死亡风险和药物剂量过量死亡风险,并描述初始和停止治疗后死亡风险趋势。

设计:系统评价和Meta分析。

数据来源:截至2016年9月的Medline、Embase、PsycINFO和LILACS。

研究选择:前瞻性或回顾性队列研究,研究对象为美沙酮或丁丙诺啡等阿片类药物替代治疗中和治疗后的随访期报告全因死亡或药物过量死亡的阿片类药物依赖的患者。

数据采集和合成:两名独立审查提取了数据并评估了研究质量。使用多变量随机效应Meta分析将治疗中和治疗后的死亡率与美沙酮或丁丙诺啡队列相结合。

结果:共有19个符合要求的队列,其中122885名患者接受美沙酮治疗1.3~13.9年,15831名患者接受丁丙诺啡治疗1.1~14.5年。美沙酮治疗中和治疗后的汇总全因死亡率分别为11.3和36.1/1000人-年(未调整治疗后与治疗中比率,3.20;95% CI,2.65~3.86),丁苯诺啡治疗中和治疗后的汇总全因死亡率分别降到4.3和9.5(2.20;1.34~3.61)。汇总趋势分析中,美沙酮治疗的首个四周后,全因死亡率急剧下降,治疗后2周逐渐降低。丁丙诺啡治疗的诱导和维持期间,全因死亡率保持稳定。药物过量死亡率的变化类似,美沙酮治疗中和治疗后的汇总药物过量死亡率分别为2.6和12.7/1000人-年(未调整治疗后与治疗中比率,4.80;95% CI,2.90~7.96),丁苯诺啡治疗中和治疗后为1.4和4.6。

结论:阿片类药物依赖的患者中,保持美沙酮和丁丙诺啡治疗与全因死亡风险和药物过量死亡风险的大幅降低相关美沙酮治疗的诱导期和两种药物治疗后迅速停药期,死亡风险尤其增加,但是公共卫生和临床策略可降低这种风险。这些结果是重要的,但是需要进行进一步的研究来合理考虑阿片类药物替代治疗间死亡风险比较中的潜在混杂因素和选取偏倚,以及每种药物的治疗期间和治疗后的各个阶段。

原始出处:

Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017 Apr 26;357:j1550. doi: 10.1136/bmj.j1550.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1695701, encodeId=5b041695e0167, content=<a href='/topic/show?id=a6948e7452c' target=_blank style='color:#2F92EE;'>#药物成瘾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87745, encryptionId=a6948e7452c, topicName=药物成瘾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e6429864127, createdName=tidiq, createdTime=Wed Aug 02 07:59:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692843, encodeId=fe2a1692843d0, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Tue Jun 06 01:59:00 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848315, encodeId=1079184831597, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Aug 15 11:59:00 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253027, encodeId=c8e6125302e07, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Mon May 29 00:59:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255642, encodeId=ac831255642e4, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon May 29 00:59:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309045, encodeId=7261130904559, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon May 29 00:59:00 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1695701, encodeId=5b041695e0167, content=<a href='/topic/show?id=a6948e7452c' target=_blank style='color:#2F92EE;'>#药物成瘾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87745, encryptionId=a6948e7452c, topicName=药物成瘾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e6429864127, createdName=tidiq, createdTime=Wed Aug 02 07:59:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692843, encodeId=fe2a1692843d0, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Tue Jun 06 01:59:00 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848315, encodeId=1079184831597, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Aug 15 11:59:00 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253027, encodeId=c8e6125302e07, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Mon May 29 00:59:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255642, encodeId=ac831255642e4, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon May 29 00:59:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309045, encodeId=7261130904559, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon May 29 00:59:00 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1695701, encodeId=5b041695e0167, content=<a href='/topic/show?id=a6948e7452c' target=_blank style='color:#2F92EE;'>#药物成瘾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87745, encryptionId=a6948e7452c, topicName=药物成瘾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e6429864127, createdName=tidiq, createdTime=Wed Aug 02 07:59:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692843, encodeId=fe2a1692843d0, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Tue Jun 06 01:59:00 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848315, encodeId=1079184831597, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Aug 15 11:59:00 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253027, encodeId=c8e6125302e07, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Mon May 29 00:59:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255642, encodeId=ac831255642e4, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon May 29 00:59:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309045, encodeId=7261130904559, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon May 29 00:59:00 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
    2017-08-15 gaoxiaoe
  4. [GetPortalCommentsPageByObjectIdResponse(id=1695701, encodeId=5b041695e0167, content=<a href='/topic/show?id=a6948e7452c' target=_blank style='color:#2F92EE;'>#药物成瘾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87745, encryptionId=a6948e7452c, topicName=药物成瘾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e6429864127, createdName=tidiq, createdTime=Wed Aug 02 07:59:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692843, encodeId=fe2a1692843d0, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Tue Jun 06 01:59:00 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848315, encodeId=1079184831597, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Aug 15 11:59:00 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253027, encodeId=c8e6125302e07, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Mon May 29 00:59:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255642, encodeId=ac831255642e4, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon May 29 00:59:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309045, encodeId=7261130904559, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon May 29 00:59:00 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1695701, encodeId=5b041695e0167, content=<a href='/topic/show?id=a6948e7452c' target=_blank style='color:#2F92EE;'>#药物成瘾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87745, encryptionId=a6948e7452c, topicName=药物成瘾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e6429864127, createdName=tidiq, createdTime=Wed Aug 02 07:59:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692843, encodeId=fe2a1692843d0, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Tue Jun 06 01:59:00 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848315, encodeId=1079184831597, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Aug 15 11:59:00 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253027, encodeId=c8e6125302e07, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Mon May 29 00:59:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255642, encodeId=ac831255642e4, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon May 29 00:59:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309045, encodeId=7261130904559, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon May 29 00:59:00 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1695701, encodeId=5b041695e0167, content=<a href='/topic/show?id=a6948e7452c' target=_blank style='color:#2F92EE;'>#药物成瘾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87745, encryptionId=a6948e7452c, topicName=药物成瘾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e6429864127, createdName=tidiq, createdTime=Wed Aug 02 07:59:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692843, encodeId=fe2a1692843d0, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Tue Jun 06 01:59:00 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848315, encodeId=1079184831597, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Aug 15 11:59:00 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253027, encodeId=c8e6125302e07, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Mon May 29 00:59:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255642, encodeId=ac831255642e4, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon May 29 00:59:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309045, encodeId=7261130904559, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon May 29 00:59:00 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
    2017-05-29 lhlxtx

相关资讯

Nat Nanotechnol:梁兴杰课题组在纳米材料抗药物成瘾作用与机制研究中取得进展

当前影响人类健康和生活质量的成瘾性药物包括:鸦片、吗啡、海洛因、甲基苯丙胺、可卡因等。其中甲基苯丙胺(俗称冰毒)极易引起人体对其极其严重的精神依赖性,据2011年研究统计,仅在美国就有120万人依赖性使用甲基苯丙胺,其滥用是非常严重的世界性公共卫生问题之一。目前的临床治疗并不足以有效控制“毒瘾”,其复吸率仍高达95%。碳纳米管作为多年来备受关注新型的纳米材料,因其独特的理化性质通常作为生物支架材料

药物成瘾神经生物学机制研究获新进展

  作为研究药物成瘾神经生物学机制的一种动物模型,行为敏化已日益受到人们的关注。近日,北京大学中国药物依赖性研究所教授梁建辉带领课题组,通过实验发现了单针吗啡诱导小鼠行为敏化的新的神经生物学机制。相关成果发表在《国际神经精神药理学》、《脑研究》(Brain Research)等国际学术期刊上。   “这个结果让我们既高兴又沮丧。”梁建辉在接受《中国科学报》记者采访时表示,高兴在于对于吗啡等精神活